| 2.28 -0.055 (-2.36%) | 08-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.8  |
1-year : | 3.27 |
| Resists | First : | 2.4 |
Second : | 2.8 |
| Pivot price | 1.89 |
|||
| Supports | First : | 1.89 |
Second : | 1.58 |
| MAs | MA(5) : | 2.18 |
MA(20) : | 1.83 |
| MA(100) : | 2.51 |
MA(250) : | 3.24 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 91.8 |
D(3) : | 94.9 |
| RSI | RSI(14): 74.8 |
|||
| 52-week | High : | 6.3 | Low : | 1.58 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ NGEN ] has closed below upper band by 5.9%. Bollinger Bands are 9.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.4 - 2.41 | 2.41 - 2.42 |
| Low: | 2.22 - 2.23 | 2.23 - 2.24 |
| Close: | 2.26 - 2.28 | 2.28 - 2.3 |
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Thu, 20 Aug 2026
NervGen (NGEN) Earnings Update: Available Metrics Are Broadly Near Expectations in the Latest Reading; Stock Move - vinanet.vn
Mon, 20 Jul 2026
Certain Common Shares of NervGen Pharma Corp. are subject to a Lock-Up Agreement Ending on 21-JUL-2026. - marketscreener.com
Mon, 01 Jun 2026
NervGen (NGEN) raises US$60M in share and warrant sale for NVG-291 - Stock Titan
Fri, 22 May 2026
NervGen Pharma (NGEN) Launches $60 Million Public Offering of Sh - GuruFocus
Fri, 22 May 2026
NervGen Pharma Corp. Announces Pricing for $60 Million Underwritten Public Offering of Common Shares and Warrants - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 108 (M) |
| Shares Float | 95 (M) |
| Held by Insiders | 15.5 (%) |
| Held by Institutions | 11.1 (%) |
| Shares Short | 4,510 (K) |
| Shares Short P.Month | 4,060 (K) |
| EPS | -0.57 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.12 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -37.8 % |
| Return on Equity (ttm) | -757.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -26 (M) |
| Levered Free Cash Flow | 38 (M) |
| PE Ratio | -4 |
| PEG Ratio | 0 |
| Price to Book value | 17.53 |
| Price to Sales | 0 |
| Price to Cash Flow | -9.56 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|